Divi's Laboratories share news, announcements and annual reports
NSE: DIVISLABBSE: 532488Pharmaceuticals & BiotechnologyLarge Cap
Divi's Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 2003
Last close ₹9,558.50up ₹53.00 (0.56%)BSE ₹9,561.70
Share price at the NSE close on 28 Oct 2026. Previous close ₹9,505.50.
28 Oct: open ₹9,460.00, high ₹9,699.50, low ₹9,370.00
52-week range of traded prices to 28 Oct 2026
₹5,647.50Low, 2 Apr 2026₹9,740.00High, 24 Sep 2026
- Next results date: the board meets on 7 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,53,748 Cr50th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 86.75
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 15.14
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 20.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 7,45,04353.5% delivered
Divi's Laboratories disputes and clarifications
9 filed, newest first.
Mar 2026
Dec 2024
4 Dec · Legal
Nov 2022
Aug 2016
Aug 2012
Jul 2012
Apr 2011
4 Apr · Legal
Webcast in News channel on April 01, 2011 reporting that "Divi's Labs is looking to acquire US Biotech companies". The Company has clarified that there are no plans or discussions or negotiations to acquire any biotech Company or of any fund raising.
Aug 2009
7 Aug · Legal
Based on repeated enquiries from shareholders if any shares were purchased by the promoters / directors on 05-August-2009, we wish to clarify that the 'Disclosure' by the Directors of the Company is only for the allotment of Bonus Shares but not purchase of shares in the market
Jan 2009
28 Jan · Legal
With reference to the mails and messages circulating regarding an alleged pledging of promoter's shareholding in the company with India Bulls or some institution that: "We hereby clarify and confirm that there is no pledge, whatsoever, of any shares held by the promoter in Divi's Laboratories Limited. Infact, the promoter does not have any loans from any bank or institution."